Bladder cancer: treatment after progression. Results of the second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2020-11-19 DOI:10.17650/1726-9776-2020-16-3-135-142

L. Bolotina, I. Zaborskiy, K. Safiullin, E. V. Gurin, L. N. Volodina, E. S. Semyonova, A. A. Gurchev, O. Gladkikh, A. Zhabina, A. Tarasova

{"title":"Bladder cancer: treatment after progression. Results of the second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia","authors":"L. Bolotina, I. Zaborskiy, K. Safiullin, E. V. Gurin, L. N. Volodina, E. S. Semyonova, A. A. Gurchev, O. Gladkikh, A. Zhabina, A. Tarasova","doi":"10.17650/1726-9776-2020-16-3-135-142","DOIUrl":null,"url":null,"abstract":"Objective. There is the second generalized analysis of administration of vinflunine in real clinical practice in Russia.Materials and methods. This analysis gathered 15 patients with urothelial carcinoma treated using this medicine in 8 cancer centers in Russia. We assessed efficacy, safety profile of vinflunine in this subset of patients.Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 73.3 %, one patient demonstrated complete response. Median of response duration accounts for 3.8 months. Six-month and 1-year survival rate made up 93.3 %. Adverse events were observed in 53.5 %, with only one episode of neutropenia 4 grade.Conclusion. In our second analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, we confirm expediency to administer of vinflunine for metastatic urothelial carcinoma.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"79 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2020-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2020-16-3-135-142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Objective. There is the second generalized analysis of administration of vinflunine in real clinical practice in Russia.Materials and methods. This analysis gathered 15 patients with urothelial carcinoma treated using this medicine in 8 cancer centers in Russia. We assessed efficacy, safety profile of vinflunine in this subset of patients.Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 73.3 %, one patient demonstrated complete response. Median of response duration accounts for 3.8 months. Six-month and 1-year survival rate made up 93.3 %. Adverse events were observed in 53.5 %, with only one episode of neutropenia 4 grade.Conclusion. In our second analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, we confirm expediency to administer of vinflunine for metastatic urothelial carcinoma.

查看原文本刊更多论文

膀胱癌:进展后治疗。第二次回顾性分析vinflunin在俄罗斯转移性尿路上皮癌患者临床应用的疗效

目标。对俄罗斯实际临床应用长春氟宁的情况进行了第二次综合分析。材料和方法。该分析收集了俄罗斯8个癌症中心使用该药治疗的15例尿路上皮癌患者。我们评估了vinfluunine在这部分患者中的疗效和安全性。长春氟宁的临床疗效(完全缓解+部分缓解+病情稳定)为73.3%，1例患者完全缓解。反应持续时间中位数为3.8个月。6个月和1年生存率为93.3%。不良事件发生率为53.5%，仅有1例发生4级中性粒细胞减少症。在我们的第二个分析中，长春氟宁比随机临床试验和其他来自欧洲实际实践的研究更有效。因此，我们确认使用长春氟宁治疗转移性尿路上皮癌的便捷性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.